Enzymotec Ltd. Announces Closing of Upsized Secondary Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

MIGDAL HA'EMEQ, Israel, March 5, 2014 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq:ENZY) (the "Company") today announced the closing of a registered public offering by certain selling shareholders of 5,403,685 ordinary shares at $28.00 per share, which includes 704,828 shares purchased pursuant to the full exercise of the underwriters' option to purchase additional shares. The Company did not receive any proceeds from the sale of these shares.

BofA Merrill Lynch and Jefferies LLC acted as joint book-running managers for the offering. Wells Fargo Securities, LLC acted as lead manager for the offering. Canaccord Genuity Inc. and Wedbush Securities Inc. acted as co-managers for the offering.

The offering was made solely by means of a prospectus, copies of which may be obtained from either: BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attention: Prospectus Department or emailing dg.prospectus_requests@baml.com; or Jefferies LLC, 520 Madison Ave, 12th Floor, New York, NY 10022, 877-547-6340, email: Prospectus_Department@Jefferies.com.

A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Enzymotec Ltd.

Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies.

CONTACT: ICR Katie Turner 646-277-1228 Katie.Turner@icrinc.comSource:Enzymotec Ltd.